POTENSI Epigallocatechin-3-gallate TERMIKROENKAPSULASI NANOLIPOSOME SEBAGAI UPAYA PENCEGAHAN PENYAKIT PARKINSON
Abstrak
ABSTRACT
Background: Parkinson’s is a progressive neurodegenerative disease characterized by loss of dopamine neurons in the substantia nigra pars compacta. Nowadays, there are several management agents to treat parkinson disease, in fact, these can only treat the symptoms not the trigger factor. Epigallocatechin-3-gallate (EGCG) is the best-known bioactive component of green tea (e.g., Camellia sinensis) that has the potential in preventing Parkinson’s disease (PD). To optimize the antioxidant effect, EGCG must be encapsulated with nanoliposome as a delivery system to protect its stability and bioactivity. Objective: To determine the effectiveness of Epigallocatechin-3-gallate with nanoliposome microencapsulated in preventing parkinson disease. Method: This review utilized search engines such as Pubmed and Sciencedirect to search for articles. The main keywords used in this searching process were “Epigallocatechin-3-gallate”, “Prevention”, and “Parkinson disease” using boolean operators to get structured a specific search result. We found 10 articles that fulfill the inclusion criteria. The inclusion criteria are based on PICOS framework containing five dimensions, those are populations (parkinson patient, cell culture models of parkinson, animal models of parkinson’s disease), intervention (Epigallocatechin-3-gallate or EGCG), comparison (control), outcome (improvement of parkinson’s symptoms or decreased progressivity of parkinson disease, and study design (experimental). Result and Discussion: EGCG is proven to be safe and effective in preventing parkinson disease. Another study stated that the use of nanoliposome as a microencapsulation agent proved effective in maintaining the viability of EGCG. Conclusion: EGCG with nanoliposome microencapsulated proved effective in preventing parkinson disease.
Keywords: Epigallocatechin-3- gallate, Nanoliposome, Neuroprotective, Parkinson Disease
##plugins.generic.usageStats.downloads##
Referensi
2. Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J [Internet]. 2016;15(1):1–17. Available from: http://dx.doi.org/10.1186/s12937-016-0179-4
3. Tan LCS. Epidemiology of parkinson’s disease. Neurol Asia. 2013;18(3):231–8.
4. Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2018;109:249–57.
5. Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson’s disease biomarkers based on α-synuclein. J Neurochem. 2019;150(5):626–36.
6. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5.
7. Lee MY, Choi EJ, Lee MK, Lee JJ. Epigallocatechin gallate attenuates L-DOPA-induced apoptosis in rat PC12 cells. Nutr Res Pract. 2013;7(4):249–55.
8. Cerri S, Mus L, Blandini F. Parkinson’s Disease in Women and Men: What’s the Difference? J Parkinsons Dis. 2019;9(3):501–15.
9. Zou L qiang, Peng S feng, Liu W, Gan L, Liu W lin, Liang R hong, et al. Improved in vitro digestion stability of (-)-epigallocatechin gallate through nanoliposome encapsulation. Food Res Int [Internet]. 2014;64:492–9. Available from: http://dx.doi.org/10.1016/j.foodres.2014.07.042
10. Chen D, Kanthasamy AG, Reddy MB. EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model. Parkinsons Dis. 2015;2015.
11. Cheng CY, Barro L, Tsai ST, Feng TW, Wu XY, Chao CW, et al. Epigallocatechin‐3‐gallate‐loaded liposomes favor anti‐inflammation of microglia cells and promote neuroprotection. Int J Mol Sci. 2021;22(6):1–15.
12. Xu Q, Langley M, Kanthasamy AG, Reddy MB. Epigallocatechin Gallate has a neurorescue effect in a mouse model of Parkinson disease. J Nutr. 2017;147(10):1926–31.
13. Xu Y, Xie M, Xue J, Xiang L, Li Y, Xiao J, et al. EGCG ameliorates neuronal and behavioral defects by remodeling gut microbiota and TotM expression in Drosophila models of Parkinson’s disease. FASEB J. 2020;34(4):5931–50.
14. Zhou T, Zhu M, Liang Z. (-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson’s disease. Mol Med Rep. 2018;17(4):4883–8.
15. Zhou W, Chen L, Hu X, Cao S, Yang J. Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3β pathway in substantia nigra neurons in Parkinson rats. Neuroreport. 2019;30(2):60–5.
16. Tseng HC, Wang MH, Chang KC, Soung HS, Fang CH, Lin YW, et al. Protective Effect of (−)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats. Neurotox Res. 2020;37(3):669–82.
17. Xu Y, Zhang Y, Quan Z, Wong W, Guo J, Zhang R, et al. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson’s Disease. Neurochem Res [Internet]. 2016;41(10):2788–96. Available from: http://dx.doi.org/10.1007/s11064-016-1995-9
18. De Pace RCC, Liu X, Sun M, Nie S, Zhang J, Cai Q, et al. Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J Liposome Res. 2013;23(3):187–96.
19. Spagnuolo C, Moccia S, Russo GL. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur J Med Chem [Internet]. 2018;153:105–15. Available from: http://dx.doi.org/10.1016/j.ejmech.2017.09.001
